Ask the expert: How to spot fake Parkinson’s medicines online
Author: Caithlin NgPublished: 27 February 2020
Prep: Cook: Serves:
In the third in our expert series, we talk to Mike Isles, Executive Director of the Alliance for Safe Online Pharmacy in the EU, about the growing problem of fake Parkinson’s medicines advertised and sold online – from their shocking prevalence to top tips on how to stay safe
Firstly, could you explain to our readers what falsified medicines are?
Falsified, fake or counterfeit medicines are medicines disguising themselves as authentic. They can pose significant health risks and might contain ingredients that are of bad or toxic quality, or they might provide the wrong dosage of active ingredients or an altogether different product. They haven’t been checked for quality, safety and efficacy against the EU’s strict regulations for healthcare products, making them a real risk to your health.
You work for the Alliance for Safe Online Pharmacy. What is it and what are its key aims?
The Alliance for Safe Online Pharmacy (ASOP EU) was created in 2011 to raise public awareness about the growing problem of falsified medicines online for European patients. ASOP EU works to encourage development and maintenance of a safe and secure environment in which patients and caregivers may access medications online, if they so choose. This is a complex problem that requires a multifactorial approach – criminals are offering falsified medicines to European citizens on not just 35,000 illegally operating websites, but also through social media and e-commerce platforms.
How common are falsified Parkinson’s medications?
It is difficult to pinpoint the number of websites offering Parkinson’s medications online, but law enforcement officials around the world take down websites and seize packages – many thousands – with falsified medicines every year, including neurological medicines and other highly-coveted prescription drugs. It is clear that if there is a market for a medication, criminals will want to produce falsified versions to meet it. These illegal actors will place any potential profits above public health and patient safety, especially in areas where there is consumer demand.
What are some actions that policymakers can take?
The Falsified Medicines Directive has been an excellent lever for helping to secure the legitimate supply chain – this comprises the manufacturer, wholesaler, pharmacist and patient. However, the illegal online pharmacy websites operate outside of the highly-regulated bricks-and-mortar supply chain, so governments should look at the various points of entry that use the internet to ensure they are operating safely for the public.
How aware are people of these scams?
Ninety-six per cent of websites selling medicine are operating illegally, but a survey from ASOP EU’s website found that on average just over 50% of people are unaware of this. Having recognised the pervasive threat of illegal online drug sellers a very high proportion, in fact greater than 90%, indicated a potential change in their behaviour, such as seeking out a bricks-and-mortar pharmacy or an authentic internet pharmacy. Our educational approach appears to be working.
What are your top tips for the Parkinson’s community to safely buy medicine online?
The best tip to avoid buying medicine
from an illegal online pharmacy is to verify three main items: a licensed
pharmacist present on site, a physical address for operations, and a working
telephone number. Patients should be wary of websites that offer bulk discounts,
too-good-to-be-true prices, or outrageous results, and very importantly that do
not require a valid prescription.
Under the EU’s Falsified Medicines Directive, any retailer in a member state must also register with their local health authority to sell medicine online; they are then legally obliged to put a “common logo” on their website. In the UK, patients can check whether the seller is registered on the Medicines and Healthcare products Regulatory Agency website.
Who can the public consult if they are still unsure?
The first port of call should be their
pharmacist or other healthcare provider, who will be knowledgeable about the
situation. Because falsified medicines sold online are designed to look as much
as possible like the original product, it can be virtually impossible to tell
the difference. It is also important not to be duped into thinking that
medicines with no legitimate product licence for use in EU member states –
therefore accompanied by insufficient clinical evidence – will work and have
In addition ASOP EU and its sister non-profit organisation ASOP Global has a wealth of information about this important area, which can be found at buysaferx.pharmacy.
There are lots of people in this world who are not aware of the rigorous clinical tests to prove safety and effectiveness before a medicine receives its licence – and so people can be very vulnerable and willing to try anything because conventional medicine isn’t working or has become unaffordable.
Need to know: Mike Isles is Executive Director of the Alliance for Safe Online
Pharmacy in the EU, an organisation addressing the threat of illegal online
drug sales. He has had a long career in the pharmaceuticals industry and has
since spent the last 10 years devoting his time to patient safety issues.
At a glance: fake medicines online
Fake medicines, which can pose significant health risks, are sold on around 35,000 websites and via social media and e-commerce platforms.
96% of websites selling medicines operate illegally – but a survey suggests that over 50% of people are not aware of this.
It can be difficult to see the difference between fake and authentic medicines, as they are designed to look similar.
Internet users should confirm that an online pharmacy lists a licensed pharmacist, a physical operational address, a working telephone number and requires a valid prescription before placing an order.
Is Obama’s ‘Cures Act’ a gamechanger for Parkinson’s treatment?
What does the ‘Cures Act’ mean for people with Parkinson’s?
3 weeks ago
Plant-based compounds could treat chronic pain in Parkinson’s, study finds
A six-year study has found that chronic pain in people with Parkinson’s is linked to a gene involved with how the brain responds to cannabis compounds. The investigation examined why some people with the condition experience persistent pain – and the impact it has on their work, daily life and social relationships. Conducted by researchers at Manchester’s Salford Royal Foundation Trust, UK, and funded by Parkinson’s UK, it is the largest study to investigate chronic pain in people with Parkinson’s. Dr Monty Silverdale, consultant neurologist at Greater Manchester Centre, said: “This study is significant because it shows the important role of genetics in chronic pain in Parkinson’s. “Our findings suggest that cannabis-based compounds may be worth investigating as a treatment for pain in Parkinson’s.”
Could playing table tennis help reduce Parkinson’s symptoms?
Researchers at Fukuoka University, Japan, have found that playing table tennis may help alleviate motor symptoms in Parkinson’s. As part of the study, 12 people with Parkinson’s with an average age of 73 played a five-hour session of table tennis every week for a period of six months. The sessions were developed specifically for people with the condition by experienced table tennis players from the university’s department of sports science. The participants were evaluated after three months and at the end of the study. At both evaluations, participants had reduced symptoms – showing improvement in speech, handwriting, walking and hand tremors. Two participants reported side-effects of backache and falling. Study author Ken-ichi Inoue, MD, of Fukuoka University said: “While this study is small, the results are encouraging because they show ping pong, a relatively inexpensive form of therapy, may improve some symptoms of Parkinson’s disease. A much larger study is…
‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s
Researchers have discovered that a molecule called BT13 could have potential to treat Parkinson’s. The study, conducted by scientists from the University of Helsinki, Finland, found that mice injected with the BT13 molecule had an increase in dopamine levels in the brain. Their findings also suggested that the molecule could lead to a new drug treatment to protect the brain cells that produce dopamine. Dopamine helps coordinate movement, but people with Parkinson’s have normally lost between 70 and 80% of the brain cells that produce the neurotransmitter when they are diagnosed with the condition. Professor David Dexter, Deputy Director of Research at Parkinson’s UK – which co-funded the study – said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms. “More research is needed to turn BT13 into a treatment to be tested in clinical trials, to…